Figure 5
Individual patient meta-analysis (52) of freedom from recurrence ofP. vivax malaria (relapse prevention) in the two pivotal phase 3 studies in adults which compared tafenoquine single dose (300mg) with a low dose primaquine regimen (15mg base day for 14 days) (46,47). The dashed vertical line represents the prespecified noninferiority margin of an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine). In Southeast Asia, which has high relapse rates, tafenoquine was significantly inferior (orange highlighting) to the low dose primaquine regimen (which is considered inferior to a high dose (30mg base/day) primaquine regimen); modified from Llanos-Cuentas et al (52) with permission.